CatalystMarker
← board

IVEVF

distress 2/10 · well-funded / low risk
$3.590%today-38% from 52w high
inventivapharma.com69 employeesFounded 2011Daix, FranceBiotechnology
Revenue
pre-revenue
Liquidity
$231M
Runway
2.2 yrs
Shares 1y
0%

Price & events

-19.1% over 6M
$3.59$4.67$5.75Jan 26Apr 26Jul 261kdilution: 424B5 offering (2026-06-02)dilution: FWP offering (2026-06-02)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
-32.6%
3M
-19.1%
6M
+57.5%
1Y
-1.4%
2Y
-66.9%
5Y
-66.9%
All

Overview

Market Cap
$693.72M
Enterprise Value
$621.22M
Volume
0
52 Week Range
$2.28 – $5.75
Total Shares
193.24M
Float Shares
160.69M
% Held by Insiders
12.67%
% Held by Institutions
49.57%
Beta
0.89

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 193,236,978 · 6 offerings/1y · 0 PIPEs
  • 2026-06-02FWPoffering
  • 2026-06-02424B5offering
  • 2025-11-13FWPoffering
  • 2025-11-13424B5offering
  • 2025-11-12424B5offering
  • 2025-11-12FWPoffering
  • 2025-10-14F-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.